寡聚脱氧核苷酸能减轻流感病毒诱导的小鼠急性炎性肺损伤
|
摘要
流感是一种由流感病毒感染引起的具有高度传染性的呼吸系统疾病,上世纪3次流感爆发流行造成了上千万人死亡,且大多数为青壮年。普遍认为重症流感的死亡原因与流感病毒诱导的过激性天然免疫反应以及大量细胞因子分泌造成急性肺部炎症性损伤有密切关系。因此,抑制过激性免疫应答对流感引起的急性肺损伤的防治可能有重要作用。
我们在前期工作中设计并验证了一种命名为SAT05f的寡聚脱氧核苷酸(oligodeoxynucleotide, ODN),在体外及小鼠体内表现出选择性抑制TLR7/9活化的作用。为了研究SAT05f是否能够减轻流感病毒感染引起的小鼠急性肺损伤,我们选择FM1流感病毒株,以滴鼻的方式感染BALB/c小鼠建立了小鼠急性肺损伤模型。在此基础上,我们研究了SAT05f对小鼠急性肺损伤的干预作用。出乎意料的是,SAT05f只表现出轻度减轻肺病理损伤的作用,而作为对TLR7/9只在体外有微弱抑制作用的对照ODN(MS19)却明显地减轻了流感病毒引起急性肺组织病理损伤;抑制了小鼠的体重下降,减低了小鼠的死亡率。为了解释这种现象,我们对小鼠的肺组织中炎性细胞浸润、TNF-?和IL-10的表达水平进行了检测,结果显示:MS19能抑制小鼠肺组织中中性粒细胞浸润,且肺组织中TNF-?和IL-10的表达水平均降低。这些结果表明,MS19减轻肺损伤的作用与抑制肺组织炎症反应及TNF-?有关,是否其他机制也参与其中还有待进一步研究。
Influenza is a highly infectious respiratory disease caused by influenza virus, posing a great global infectious disease threat. In the 20th century, three influenza pandemics emerged and killed tens of millions of people. In the patients, most deaths occurred in young people, previously healthy adults or children. Analysis showed that one of the main reasons for the death was due to acute respiratory distress syndrome (ARDS) caused by influenza virus-induced inflammatory injury.
In recent years, over-activated innate immune response has been found attributable to the development of the influenza virus-induced lung inflammatory injury. Upon infection, influenza virus derived single stranded RNA and double stranded RNA, generated as intermediate molecules, are sensed by toll-like receptors (TLRs), initiating activation of the innate immune cells, such as macrophages and dentritic cells (DC). The activated cells produce type I interferon and other cytokines to combat the virus. However, if infection persists, innate immune cells could be over-activated and produce excessive pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-?), interleukin-1 (IL-1), and interleukin-6 (IL-6), undesirably. The over-produced cytokines, as found in basic and clinical studies, contribute to acute lung inflammatory injury (ALII), leading to a fatal outcome. Obviously, it is required to develop agents to curb the over-reaction and the over-produced cytokines for saving life of the patients infected with influenza virus, especially those highly pathogenic ones.
Inhibitory oligodeoxynucleotides (ODNs), an artificial single-stranded DNA molecule, could regulate innate immunity activation. Recent studies demonstrate that inhibitory ODNs show a promise to develop an agent for the treatment of diseases associated with Toll-like receptor activation,including SLE and sepsis. In our previous study, SAT05f and MS19, the MS ODNs (microsatellite DNA mimicking oligonucleotides) designed with reference of the sequence of human microsatellite DNA, were shown able to rescue mice from lethal shock.
In this study, to test whether the MS ODN could lessen ALII in mice infected by influenza virus, we firstly established the mouse model induced by influenza virus, a H1N1 mouse influenza virus. Then, we observe the effect of MS ODN on acute lung injury in FM1 virus infected mice and study the mechanism.
1. Establishment of the mouse model of acute lung inflammatory injury induced by influenza virus
It is well known that not all influenza virus strains can cause ALII, leading to severe pneumonia by over-activating innate immune response. To study whether the MS ODN could lessen the ALII of mice, FM1 virus was used to establish a mouse model. After being inoculated intranasally with 10 LD50 of FM1 virus, the mice were observed every day for recording the morbidity and the mortality. On day 2 or 3 post infection, most of the infected mice began to exhibit clinical signs of influenza, including ruffle fur, hunched posture, neurological symptoms and weight loss. To monitor the viral infection and cytokine production in lung, the mice were sacrificed at day 0, 2, 4, 6 post infection and their lungs were removed for preparing homogenates that were used to test the FM1 virus titer by hemagglutination assay and biological activity of TNF-αby L929 cytotoxicity bioassay. The results showed that the viral titer in lung homogenate in mice began to increase on day 2, and rapidly decreased on day 4 post infection. On day 6 post infection, the virus titer in the lung homogenate was hardly detected. Interestingly, on day 6, the infected mice began to die. Within ten days, all the infected mice succumbed. Obviously, the highest virus load was not directly attributed to the death, suggesting the involvement of other factors.
To analyze the mechanism of acute lung injury of mice induced by influenza virus, we observe the curve of virus titer and pro-inflammation cytokines. On day 0, the mice infected 10LD50 influenza virus. On day 2, 4, and 6 post-infection, the mice were scracificed and their lungs were homogenated. The results shown that the virus titer increased gradually from day 2, reached to the maximum on day 4 and decresed on day 6 a time point when the mice began to die, indicating that the virus titer was not associated with the death. Interestingly, he TNF-α, an important pro-inflammatory factor for inducing ALII, rose rapidly in the lung on day 2 post infection and then maintained at a high level to the day 6, implying a role of TNF-αfor the death. Upon the results, the mouse infected with FM1 virus was adopted as an animal model to evaluate the effects of MS ODN on the ALII caused by FM1, possibly by modulating innate immune responses.
2. The inhibitory effect of MS ODN on TLR7/9 mediated activation in innate immune response in vitro
We choose three MS ODNs, named as SAT05f, MS19 and MS33. We test the effect of MS ODNs on inhibiton of TLR9 agonist (CpG 1826) induced the proliferation of mouse spleen cells and the production of TNF-α. In addition, we also test the the effect of MS ODNs on inhibiton of TLR7 agonist (PR8-flu, inactivated FM1 virus) induced the production of TNF-αfrom RAW264.7. a) The effect of MS ODN on inhibition of CpG 1826 induced the proliferation of mouse spleen cells and the procution of TNF-αfrom RAW264.7.
To observe the inhibition of MS ODN on the activiton of immune cells, we firstly isolated the mouse spleen cells. In the assay, CpG 1826 (B type CpG ODN), capable of stimulating the proliferation of mouse spleen cells, was chosen as a stimulator. Freshly isolated mouse spleen cells were incubated in the medium containing CpG 1826 alone or with SAT05f or MS19 or MS33 and then assessed for their proliferation by MTT assay. The result showed that SAT05f were capable of inhibiting CpG 1826-induced proliferation of mouse spleen cells significantly (p<0.01). MS19 and MS33 failed to inhibit the CpG 1826-induced proliferation.
To determine whether MS ODNs could block the production of TNF-α, a pro-inflammatory cytokine involved in lung inflammatory injury caused by influenza virus infection (Clark, 2007), we detected the inhibitory effect of MS ODNs on blocking TNF-αproduction from RAW264.7 cells (a murine macrophage-like cell line cells) induced by CpG 1826 (B type CpG ODN) that was confirmed capable of stimulating the production of TNF-αfrom immune cells. The results showed that SAT05f could significantly inhibit the TNF-αproduction from RAW264.7 cells
b) The effect of MS ODN on inhibition of TLR7 agonist induced anti-viral activity and the procution of TNF-αfrom RAW264.7
To determine whether MS ODNs could block the production of TNF-αby blocking the TLR7, we detected the inhibitory effect of MS ODNs on blocking TNF-αproduction from RAW264.7 cells (a murine macrophage-like cell line cells) induced by inactivated FM1. The results showed that SAT05f could significantly inhibit the anti-VSV activity induced by PR8-flu and the TNF-αproduction from RAW264.7 cells triggered by FM1 (p<0.01), While MS19 and MS33 failed to.
3. The effect of MS ODN on the morbidity, mortality, and lung inflammatory injury of mice infected with influenza virus.
Upon these, a microsatellite DNA mimicking oligodeoxynucleotide (MS ODN), named as SAT05f capable of inhibiting TLR7/9-activation in vitro, was used to treat mice infected with FM1 virus. In parallel, two MS ODNs confirmed with less or no in vitro activities, named as MS19 and MS33, were used as controls. On day 0, mice were inoculated intranasally with 10 LD50 of FM1 virus. The mice (n=8) sham-inoculated with sterile PBS were used as normal control. On days 2 and 4 post infection, the model mice (n=8) were injected i.p. with PBS, SAT05f or MS19 or MS33, respectively. We observed the effect of MS ODN on the morbidity, mortality, and lung inflammatory injury of mice infected with influenza virus.
a) The effect of MS ODN on weight loss and survival of mice infected with influenza virus.
Unexpectively, On day 7 post infection, the model mice received PBS or SAT05f or MS19 displayed 31%, 30% and 29%,mean weight loss at day 7, respectively, while model mice treated with MS19 only displayed 22 % mean weight loss, indicated that MS19 significantly inhibit the weight loss of mice infected influenza virus. While SAT05f displayed a weaker role. On day 16, the mortality rates of the mice treated with PBS and MS33 successively increased to 87.5% and 100%, whereas the mortality rates of the mice treated with SAT05f or MS19 decreased to 62.5% or 37.5%, respectively.
b) The effect of MS ODN on lung inflammatory injury of mice infected with influenza virus.
On day 17, the survived mice in each group and normal control mice were sacrificed and their lungs and spleens were removed for gross observation, histopathological examination and body weight measurement. The whole lungs of the mice treated with PBS and MS33 displayed edema, consolidation and profuse hemorrhage. Comparably, in the mice treated with SAT05f, the consolidated change and profuse hemorrhage only occurred on 25% areas of the lung. Unexpectedly, MS19, an ODN unable to inhibit TLR7/9 activation in vitro, could almost completely prohibit the development of the consolidation and hemorrhage in lung of the mice. Histopathologically, mice treated PBS showed thickened and congested alveolar walls, intra-alveolar edema, and numerous infiltrated leukocytes. In contrast, the lung of the mice treated with SAT05f, the areas with thickened alveolar walls, intra-alveolar edema and infiltrated leukocytes were fewer. The lung of the mice treated with MS19 manifested thinner alveolar walls, lacking intra-alveolar edema fluid and infiltrated leukocytes. Furthermore, the pathological score of the lung tissue of MS19-treated mice was lower than that in the mice treated with PBS and SAT05f group. The data indicated that MS19 could lessen the ALII of mice infected with influenza virus.
c) The effect of MS ODN on lung index and spleen index of mice infected with influenza virus.
Based on the weights of the lungs and spleens of the sacrificed mice, lung index (lung weight/body weight) and spleen index (spleen weight/body weight) were determined. The lung index of the mice infected with FM1 virus increased significantly, compared to that in normal mice, indicating that a strong inflammatory reaction was induced by FM1 virus in lung of the model mice. The lung index of the mice in MS19 group was lower than that in the PBS group, implying that MS19 could significantly inhibit the FM1 virus-induced ALII. The inhibition was correlated with the inhibitory effect of MS19 on immune reactions, manifested by that the spleen index of the mice received MS19 was 6.29±1.32; in contrast, that in the mice treated with PBS was 11.79. The spleen index of the mice in MS19 group was as low as that in the normal control group.
d) The effect of MS ODN on the infliltration of immune cells and production of inflammatory cytokines in lung tissue of mice infected with influenza virus. To find how MS ODN inhibited the development of ALII caused by FM1 virus, we detected the the infliltration of immune cells and production of inflammatory cytokines in lung tissues of the mice infected with FM1 virus. The results showed that MS19 significantly inhibit the infiltrated immune cells. In addition, we test the mRNA levels of TNF-αand IL-10 in the lung tissues of mice. The results showed that MS19 significantly inhibit the expression of TNF-αand IL-10 in the lung tissues. In addition, MS19 could inhibit TNF-αproduction induced by FM1 virus.
e) The effect of MS ODN on the virus titer in lung tissue of mice infected with influenza virus.
Upon that the FM1 virus titer reached its peak in lungs of the model mice, as determined above, we detected the FM1 virus titers in the homogenates collected on day 4 after infection. FM1 virus titers in lung homogenates of the mice treated with MS19 was within the same range as that of the homogenates from the mice treated with PBS, suggesting that MS19 mediated inhibition on the development of ALII induced by FM1 virus was unrelated to the direct action of MS19 on replication of FM1 virus.
In present study, we found that MS19 significantly inhibited the weight loss and displayed dramatic effect on lessening the ALII by reducing consolidation, hemorrhage, intra-alveolar edema and leukocyte infiltration in lungs of the mice. Meanwhile, MS19 could prolong the survival of the mice. The data suggest that MS19 might be developed a candidate drug for the treatment of acute lung injury induced by other virus.
我们在前期工作中设计并验证了一种命名为SAT05f的寡聚脱氧核苷酸(oligodeoxynucleotide, ODN),在体外及小鼠体内表现出选择性抑制TLR7/9活化的作用。为了研究SAT05f是否能够减轻流感病毒感染引起的小鼠急性肺损伤,我们选择FM1流感病毒株,以滴鼻的方式感染BALB/c小鼠建立了小鼠急性肺损伤模型。在此基础上,我们研究了SAT05f对小鼠急性肺损伤的干预作用。出乎意料的是,SAT05f只表现出轻度减轻肺病理损伤的作用,而作为对TLR7/9只在体外有微弱抑制作用的对照ODN(MS19)却明显地减轻了流感病毒引起急性肺组织病理损伤;抑制了小鼠的体重下降,减低了小鼠的死亡率。为了解释这种现象,我们对小鼠的肺组织中炎性细胞浸润、TNF-?和IL-10的表达水平进行了检测,结果显示:MS19能抑制小鼠肺组织中中性粒细胞浸润,且肺组织中TNF-?和IL-10的表达水平均降低。这些结果表明,MS19减轻肺损伤的作用与抑制肺组织炎症反应及TNF-?有关,是否其他机制也参与其中还有待进一步研究。
Influenza is a highly infectious respiratory disease caused by influenza virus, posing a great global infectious disease threat. In the 20th century, three influenza pandemics emerged and killed tens of millions of people. In the patients, most deaths occurred in young people, previously healthy adults or children. Analysis showed that one of the main reasons for the death was due to acute respiratory distress syndrome (ARDS) caused by influenza virus-induced inflammatory injury.
In recent years, over-activated innate immune response has been found attributable to the development of the influenza virus-induced lung inflammatory injury. Upon infection, influenza virus derived single stranded RNA and double stranded RNA, generated as intermediate molecules, are sensed by toll-like receptors (TLRs), initiating activation of the innate immune cells, such as macrophages and dentritic cells (DC). The activated cells produce type I interferon and other cytokines to combat the virus. However, if infection persists, innate immune cells could be over-activated and produce excessive pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-?), interleukin-1 (IL-1), and interleukin-6 (IL-6), undesirably. The over-produced cytokines, as found in basic and clinical studies, contribute to acute lung inflammatory injury (ALII), leading to a fatal outcome. Obviously, it is required to develop agents to curb the over-reaction and the over-produced cytokines for saving life of the patients infected with influenza virus, especially those highly pathogenic ones.
Inhibitory oligodeoxynucleotides (ODNs), an artificial single-stranded DNA molecule, could regulate innate immunity activation. Recent studies demonstrate that inhibitory ODNs show a promise to develop an agent for the treatment of diseases associated with Toll-like receptor activation,including SLE and sepsis. In our previous study, SAT05f and MS19, the MS ODNs (microsatellite DNA mimicking oligonucleotides) designed with reference of the sequence of human microsatellite DNA, were shown able to rescue mice from lethal shock.
In this study, to test whether the MS ODN could lessen ALII in mice infected by influenza virus, we firstly established the mouse model induced by influenza virus, a H1N1 mouse influenza virus. Then, we observe the effect of MS ODN on acute lung injury in FM1 virus infected mice and study the mechanism.
1. Establishment of the mouse model of acute lung inflammatory injury induced by influenza virus
It is well known that not all influenza virus strains can cause ALII, leading to severe pneumonia by over-activating innate immune response. To study whether the MS ODN could lessen the ALII of mice, FM1 virus was used to establish a mouse model. After being inoculated intranasally with 10 LD50 of FM1 virus, the mice were observed every day for recording the morbidity and the mortality. On day 2 or 3 post infection, most of the infected mice began to exhibit clinical signs of influenza, including ruffle fur, hunched posture, neurological symptoms and weight loss. To monitor the viral infection and cytokine production in lung, the mice were sacrificed at day 0, 2, 4, 6 post infection and their lungs were removed for preparing homogenates that were used to test the FM1 virus titer by hemagglutination assay and biological activity of TNF-αby L929 cytotoxicity bioassay. The results showed that the viral titer in lung homogenate in mice began to increase on day 2, and rapidly decreased on day 4 post infection. On day 6 post infection, the virus titer in the lung homogenate was hardly detected. Interestingly, on day 6, the infected mice began to die. Within ten days, all the infected mice succumbed. Obviously, the highest virus load was not directly attributed to the death, suggesting the involvement of other factors.
To analyze the mechanism of acute lung injury of mice induced by influenza virus, we observe the curve of virus titer and pro-inflammation cytokines. On day 0, the mice infected 10LD50 influenza virus. On day 2, 4, and 6 post-infection, the mice were scracificed and their lungs were homogenated. The results shown that the virus titer increased gradually from day 2, reached to the maximum on day 4 and decresed on day 6 a time point when the mice began to die, indicating that the virus titer was not associated with the death. Interestingly, he TNF-α, an important pro-inflammatory factor for inducing ALII, rose rapidly in the lung on day 2 post infection and then maintained at a high level to the day 6, implying a role of TNF-αfor the death. Upon the results, the mouse infected with FM1 virus was adopted as an animal model to evaluate the effects of MS ODN on the ALII caused by FM1, possibly by modulating innate immune responses.
2. The inhibitory effect of MS ODN on TLR7/9 mediated activation in innate immune response in vitro
We choose three MS ODNs, named as SAT05f, MS19 and MS33. We test the effect of MS ODNs on inhibiton of TLR9 agonist (CpG 1826) induced the proliferation of mouse spleen cells and the production of TNF-α. In addition, we also test the the effect of MS ODNs on inhibiton of TLR7 agonist (PR8-flu, inactivated FM1 virus) induced the production of TNF-αfrom RAW264.7. a) The effect of MS ODN on inhibition of CpG 1826 induced the proliferation of mouse spleen cells and the procution of TNF-αfrom RAW264.7.
To observe the inhibition of MS ODN on the activiton of immune cells, we firstly isolated the mouse spleen cells. In the assay, CpG 1826 (B type CpG ODN), capable of stimulating the proliferation of mouse spleen cells, was chosen as a stimulator. Freshly isolated mouse spleen cells were incubated in the medium containing CpG 1826 alone or with SAT05f or MS19 or MS33 and then assessed for their proliferation by MTT assay. The result showed that SAT05f were capable of inhibiting CpG 1826-induced proliferation of mouse spleen cells significantly (p<0.01). MS19 and MS33 failed to inhibit the CpG 1826-induced proliferation.
To determine whether MS ODNs could block the production of TNF-α, a pro-inflammatory cytokine involved in lung inflammatory injury caused by influenza virus infection (Clark, 2007), we detected the inhibitory effect of MS ODNs on blocking TNF-αproduction from RAW264.7 cells (a murine macrophage-like cell line cells) induced by CpG 1826 (B type CpG ODN) that was confirmed capable of stimulating the production of TNF-αfrom immune cells. The results showed that SAT05f could significantly inhibit the TNF-αproduction from RAW264.7 cells
b) The effect of MS ODN on inhibition of TLR7 agonist induced anti-viral activity and the procution of TNF-αfrom RAW264.7
To determine whether MS ODNs could block the production of TNF-αby blocking the TLR7, we detected the inhibitory effect of MS ODNs on blocking TNF-αproduction from RAW264.7 cells (a murine macrophage-like cell line cells) induced by inactivated FM1. The results showed that SAT05f could significantly inhibit the anti-VSV activity induced by PR8-flu and the TNF-αproduction from RAW264.7 cells triggered by FM1 (p<0.01), While MS19 and MS33 failed to.
3. The effect of MS ODN on the morbidity, mortality, and lung inflammatory injury of mice infected with influenza virus.
Upon these, a microsatellite DNA mimicking oligodeoxynucleotide (MS ODN), named as SAT05f capable of inhibiting TLR7/9-activation in vitro, was used to treat mice infected with FM1 virus. In parallel, two MS ODNs confirmed with less or no in vitro activities, named as MS19 and MS33, were used as controls. On day 0, mice were inoculated intranasally with 10 LD50 of FM1 virus. The mice (n=8) sham-inoculated with sterile PBS were used as normal control. On days 2 and 4 post infection, the model mice (n=8) were injected i.p. with PBS, SAT05f or MS19 or MS33, respectively. We observed the effect of MS ODN on the morbidity, mortality, and lung inflammatory injury of mice infected with influenza virus.
a) The effect of MS ODN on weight loss and survival of mice infected with influenza virus.
Unexpectively, On day 7 post infection, the model mice received PBS or SAT05f or MS19 displayed 31%, 30% and 29%,mean weight loss at day 7, respectively, while model mice treated with MS19 only displayed 22 % mean weight loss, indicated that MS19 significantly inhibit the weight loss of mice infected influenza virus. While SAT05f displayed a weaker role. On day 16, the mortality rates of the mice treated with PBS and MS33 successively increased to 87.5% and 100%, whereas the mortality rates of the mice treated with SAT05f or MS19 decreased to 62.5% or 37.5%, respectively.
b) The effect of MS ODN on lung inflammatory injury of mice infected with influenza virus.
On day 17, the survived mice in each group and normal control mice were sacrificed and their lungs and spleens were removed for gross observation, histopathological examination and body weight measurement. The whole lungs of the mice treated with PBS and MS33 displayed edema, consolidation and profuse hemorrhage. Comparably, in the mice treated with SAT05f, the consolidated change and profuse hemorrhage only occurred on 25% areas of the lung. Unexpectedly, MS19, an ODN unable to inhibit TLR7/9 activation in vitro, could almost completely prohibit the development of the consolidation and hemorrhage in lung of the mice. Histopathologically, mice treated PBS showed thickened and congested alveolar walls, intra-alveolar edema, and numerous infiltrated leukocytes. In contrast, the lung of the mice treated with SAT05f, the areas with thickened alveolar walls, intra-alveolar edema and infiltrated leukocytes were fewer. The lung of the mice treated with MS19 manifested thinner alveolar walls, lacking intra-alveolar edema fluid and infiltrated leukocytes. Furthermore, the pathological score of the lung tissue of MS19-treated mice was lower than that in the mice treated with PBS and SAT05f group. The data indicated that MS19 could lessen the ALII of mice infected with influenza virus.
c) The effect of MS ODN on lung index and spleen index of mice infected with influenza virus.
Based on the weights of the lungs and spleens of the sacrificed mice, lung index (lung weight/body weight) and spleen index (spleen weight/body weight) were determined. The lung index of the mice infected with FM1 virus increased significantly, compared to that in normal mice, indicating that a strong inflammatory reaction was induced by FM1 virus in lung of the model mice. The lung index of the mice in MS19 group was lower than that in the PBS group, implying that MS19 could significantly inhibit the FM1 virus-induced ALII. The inhibition was correlated with the inhibitory effect of MS19 on immune reactions, manifested by that the spleen index of the mice received MS19 was 6.29±1.32; in contrast, that in the mice treated with PBS was 11.79. The spleen index of the mice in MS19 group was as low as that in the normal control group.
d) The effect of MS ODN on the infliltration of immune cells and production of inflammatory cytokines in lung tissue of mice infected with influenza virus. To find how MS ODN inhibited the development of ALII caused by FM1 virus, we detected the the infliltration of immune cells and production of inflammatory cytokines in lung tissues of the mice infected with FM1 virus. The results showed that MS19 significantly inhibit the infiltrated immune cells. In addition, we test the mRNA levels of TNF-αand IL-10 in the lung tissues of mice. The results showed that MS19 significantly inhibit the expression of TNF-αand IL-10 in the lung tissues. In addition, MS19 could inhibit TNF-αproduction induced by FM1 virus.
e) The effect of MS ODN on the virus titer in lung tissue of mice infected with influenza virus.
Upon that the FM1 virus titer reached its peak in lungs of the model mice, as determined above, we detected the FM1 virus titers in the homogenates collected on day 4 after infection. FM1 virus titers in lung homogenates of the mice treated with MS19 was within the same range as that of the homogenates from the mice treated with PBS, suggesting that MS19 mediated inhibition on the development of ALII induced by FM1 virus was unrelated to the direct action of MS19 on replication of FM1 virus.
In present study, we found that MS19 significantly inhibited the weight loss and displayed dramatic effect on lessening the ALII by reducing consolidation, hemorrhage, intra-alveolar edema and leukocyte infiltration in lungs of the mice. Meanwhile, MS19 could prolong the survival of the mice. The data suggest that MS19 might be developed a candidate drug for the treatment of acute lung injury induced by other virus.
引文
[1] Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, Naghdaliyev A, Peiris JS, Shindo N, Soeroso S, Uyeki TM. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261–273.
[2] Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M, Bouvier M. Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci U S A. 2000; 97:3684-9.
[3] Balasubramanian V, Nguyen LT, Balasubramanian SV, Ramanathan M. Interferon gamma inhibitory oligodeoxynucleotides alter the conformation of interferongamma. Mol Pharmacol. 1998; 53:926-32.
[4] Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O,Coffman RL. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-likereceptors and may promote systemic lupus erythematosus. J Exp Med. 2005; 202:1131-9.
[5] Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol. 2007; 37: 3582-6.
[6] Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS,Kettner JD, Kumar A, Lim M, Shindo N, Penn C, Nicholson KG. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010; 362:1708–19.
[7] Bazin HG, Murray TJ, Bowen WS, Mozaffarian A, Fling SP, Bess LS, Livesay MT, Arnold JS, Johnson CL,Ryter KT, Cluff CW, Evans JT, Johnson DA. The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics. Bioorg Med Chem Lett. 2008;18:5350-4.
[8] Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, Lochindarat S, Nguyen TK, Nguyen TH, Tran TH, Nicoll A, Touch S, Yuen KY. Avian influenza A (H5N1) infection in humans.N. N Engl J Med. 2005; 353: 1374-85.
[9] Blazejewska P, Koscinski L, Viegas N, Anhlan D, Ludwig S, Schughart K. Pathogenicity of different PR8 influenza A virus variants in mice is determined by both viral and host factors. Virology. 2011; 412: 36-45.
[10] Budd A, Alleva L, Alsharifi M, Koskinen A, Smythe V, Müllbacher A, Wood J, Clark I. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother. 2007; 51: 2965-8.
[11] Carey MA, Bradbury JA, Seubert JM, Langenbach R, Zeldin DC,Germolec DR. Contrasting effects of cyclooxygenase-1 (COX-1)and COX-2 deficiency on the host response to influenza A viralinfection. J Immunol. 2005; 175: 6878-84.
[12] Chan MC, Cheung CY, Chui WH, Tsao SW, Nicholls JM, Chan YO, Chan RW, Long HT, Poon LL, Guan Y, Peiris JS. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronehial epithelial cells. Respir Res. 2005; 6: 135.
[13] Chen J, Deng YM. Influenza virus antigenic variation, host antibody production and new approach to control epidemics. Virol J. 2009; 6: 30.
[14] Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF, Gordon S, Guan Y, Peiris JS. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet. 2002; 360: 1831-7.
[15] Choudhury BK, Wild JS, Alam R, Klinman DM, Boldogh I, Dharajiya N, Mileski WJ, Sur S. In vivo role of p38 mitogen-activated protein kinase in mediating the anti-inflammatory effects of CpG oligodeoxynucleotide in murine asthma. J Immunol. 2002; 169: 5955-61.
[16] Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA,Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006; 25:417-28.
[17] Clark IA.How TNF was recognized as a key mechanism of disease.Cytokine Growth Factor Rev. 2007; 18: 335-43.
[18] Couillin I, Vasseur V, Charron S, Gasse P, Tavernier M, Guillet J, Lagente V, Fick L, Jacobs M, Coelho FR, Moser R, Ryffel B. IL-1R1/MyD88 signaling is critical for elastase-induced lung inflammation and emphysema. J Immunol. 2009; 183: 8195-202.
[19] de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Chau NV, Khanh TH, Dong VC, Qui PT, Cam BV, Ha do Q, Guan Y, Peiris JS, Chinh NT, Hien TT, Farrar J. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006; 12: 1203-7.
[20] Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligonucleotides protect against collagen-induced arthritis in mice. Arthritis Rheum. 2004; 50: 1686-9.
[21] Dybing, J.K., Schultz-Cherry, S., Swayne, D.E., Suarez, D.L., Perdue, M.L. Distinct pathogenesis of Hong Kong—origin H5N1 viruses in mice compared to that ofother highly pathogenic H5 avian influenza viruses. J Virol. 2000; 74: 1443-50.
[22] Ferrandiz ML, Foster SJ. Tumor necrosis factor production in a rat airpouch model of inflammation: role of eicosanoids. Agents Actions. 1991; 32:289–294.
[23] Francis T Jr. A new type of virus from epidemic influenza. Science. 1940; 92: 405–408.
[24] Fritz RS, Hayden FG, Calfee DP, Cass LM, Peng AW, Alvord WG, Strober W, Straus SE. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis. 1999; 180: 586-93.
[25] Gambaryan AS, Boravleva EY, Matrosovich TY, Matrosovich MN, Klenk HD, Moiseeva EV, Tuzikov AB, Chinarev AA, Pazynina GV, Bovin NV. Polymer-bound 6_sialyl-N-acetyllactosamine protects mice infectedby influenza virus. Antiviral Res. 2005; 68:116-23.
[26] Gamblin SJ, Skehel JJ. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem. 2010; 285: 28403-9.
[27] Ghedin E, Sengamalay NA, Shumway M, Zaborsky J, Feldblyum T, Subbu V, Spiro DJ, Sitz J, Koo H, Bolotov P, Dernovoy D, Tatusova T, Bao Y, St George K, Taylor J, Lipman DJ, Fraser CM, Taubenberger JK, Salzberg SL.Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature. 2005; 437: 1162-1166.
[28] Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, Si-Tahar M. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem. 2005; 280: 5571-80.
[29] Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F, Klinman DM. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol. 2003; 171:1393-400.
[30] Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F, Klinman DM. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol. 2003; 171: 1393-400.
[31] Haas T, Metzger J, Schmitz F, Heit A, Müller T, Latz E, Wagner H. The DNA sugar backbone 2’deoxyribose determines toll-like receptor 9 activation. Immunity. 2008; 28: 315-23.
[32] Hacker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med. 2000; 192: 595-600.
[33] Halpern MD, Pisetsky DS. In vitro inhibition of murine IFN gamma production by phosphorothioate deoxyguanosine oligomers.Immunopharmacology. 1995; 29: 47-52.
[34] Hashimoto C, Hudson KL, Anderson KV. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell. 1988; 52: 269-79.
[35] Hatta M, Kawaoka Y. Clue to the molecular mechanism of virulence of highly pathogenic H5N1 avian influenza viruses isolated in 2004. Uirusu. 2005; 55: 55-61.
[36] Hatta M, Hatta Y, Kim JH, Watanabe S, Shinya K, Nguyen T, Lien PS, Le QM, Kawaoka Y. Growth of H5N1 influenza A viruses in the upper respiratory tracts of mice. PLoS Pathog. 2007; 3: 1374-9.
[37] Hayashi K, Kadowaki SE, Takei M, Fukuda H. Efficacy of quinolones against secondary pneumococcal pneumonia after influenza virus infection in mice. Antimicrob Agents Chemother. 2006; 50: 748-51.
[38] Heer AK, Shamshiev A, Donda A, Uematsu S, Akira S, Kopf M, Marsland BJ. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J Immunol 2007; 178: 2182-2191.
[39] Heinz S, Haehnel V, Karaghiosoff M, Schwarzfischer L, Müller M, Krause SW, Rehli M. Species-specific regulation of Toll-like receptor 3 genes in men and mice. J Biol Chem. 2003; 278: 21502-9.
[40] Ho PP, Fontoura P, Ruiz PJ, Steinman L, Garren H. An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J Immunol. 2003; 171:4920-6.
[41] Hoppstadter J, Diesel B, Zarbock R, Breinig T, Monz D, Koch M, Meyerhans A, Gortner L, Lehr CM, Huwer H, Kiemer AK. Differential cell reaction upon Toll-like receptor 4 and 9 activation in human alveolar and lung interstitial macrophages. Respir Res. 2010; 11: 124.
[42] Hu D, Su X, Sun R, Yang G, Wang H, Ren J, Sun L, Wu X, Hu X, Yu Y, Wang L. Human microsatellite DNA mimicking oligodeoxynucleotides down-regulate TLR9-dependent and -independent activation of human immune cells. Mol Immunol. 2009; 46: 1387-96.
[43] Hussell T, Pennycook A, Openshaw PJ. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol. 2001; 31: 2566-73.
[44] Inohara, Chamaillard, McDonald C, Nu?ez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem. 2005; 74: 355-83.
[45] Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med. 2002; 76: 105-15.
[46] Julkunen I, Melén K, Nyqvist M, Pirhonen J, Sareneva T, Matikainen S. Inflammatory responses in influenza A virus infection. Vaccine. 2000; 19: 32-7.
[47] Karen H. TLR ligands from the natural world. Nature Reviews Immunology. 2006; 177: 7114-21.
[48] Kash JC, Tumpey TM, Proll SC, Carter V, Perwitasari O, Thomas MJ, Basler CF, Palese P, Taubenberger JK, García-Sastre A, Swayne DE, Katze MG. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature. 2006; 443: 578-81.
[49] Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T, Akira S. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006; 441: 101-5.
[50] Katz JM, Lu X, Frace AM, Morken T, Zaki SR, Tumpey TM. Pathogenesisof and immunity to avian influenza A H5 viruses. Biomed Pharmacother. 2000; 54: 178-87.
[51] Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol. 2009; 21: 317-37.
[52] Kawai T, Akira S. Toll-like receptor downstream signaling. Arthritis Res Ther. 2005; 7: 12-9.
[53] Kawaoka Y, Krauss S, Webster RG. Avian-to-human transmission of thePB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol. 1989; 63: 4603-8.
[54] Kido H, Yokogoshi Y, Sakai K, Tashiro M, Kishino Y, Fukutomi A, Katunuma N. Isolation and characterization of a noveltrypsin-like protease found in rat bronchiolar epithelial clara cells. J Biol Chem. 1992; 267: 13573-9.
[55] Killian ML. Hemagglutination Assay for the Avian Influenza Virus. Methods Mol Biol. 2008; 436: 47-52.
[56] Klinman DM, Tross D, Klaschik S, Shirota H, Sato T. Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides.Ann N Y Acad Sci. 2009; 1175: 80-8.
[57] Knuefermann P, Baumgarten G, Koch A, Schwederski M, Velten M, Ehrentraut H, Mersmann J, Meyer R, Hoeft A, Zacharowski K, GrohéC. CpG oligonucleotide activates Toll-like receptor 9 and causes lung inflammation in vivo. Respir Res. 2007; 8: 72.
[58] Korteweg C, Gu J. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am J Pathol, 2008; 172: 1155-1170
[59] Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara H, Hatta Y, Kim JH, Halfmann P, Hatta M,Feldmann F, Alimonti JB, Fernando L, Li Y, Katze MG, Feldmann H, Kawaoka Y. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature. 2007; 445: 319-23.
[60] Korteweg C, Gu J. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am J Pathol. 2008; 172: 1155-70.
[61] Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, Yi AK, Short D, Davis HL. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci. 1998; 95:12631-6.
[62] Krieg AM. CpG DNA: a pathogenic factor in systemic lupus erythematosus?J Clin Immunol. 1995; 15: 284-92.
[63] Krysko DV, Kaczmarek A, Krysko O, Heyndrickx L, Woznicki J, Bogaert P, Cauwels A, Takahashi N, Magez S, Bachert C, Vandenabeele P. TLR-2 and TLR-9 are sensors of apoptosis in a mouse model of doxorubicin-induced acute inflammation. Cell Death Differ. 2011; 18: 1316-25.
[64] Lafferty EI, Qureshi ST, Schnare M. The role of toll-like receptors in acute and chronic lung inflammation.J Inflamm. 2010; 7: 57.
[65] Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T,Golenbock DT. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 2004; 5:190-8.
[66] Lenert P. Inhibitory oligodeoxynucleotides-therapeutic promise for systemic autoimmune diseases? Clin Exp Immunol. 2005; 140:1-10.
[67] Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, Flavell R,Chignard M, Si-Tahar M. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog 2006:2:e53.
[68] Le Goffic R, Pothlichet J, Vitour D, Fujita T, Meurs E, Chignard M, Si-Tahar M.Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J Immunol. 2007; 178: 3368-72.
[69] Le Goffic R, Pothlichet J, Vitour D, Fujita T, Meurs E, Chignard M, Si-Tahar M. Cutting edge: influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J Immunol. 2007; 178: 3368-72.
[70] Lee N, Wong CK, Chan PK, Lun SW, Lui G, Wong B, Hui DS, Lam CW, Cockram CS, Choi KW, Yeung AC,Tang JW, Sung JJ. Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. Clin InfectDis. 2007; 45: 723-31.
[71] Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette sp?tzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell. 1996; 86: 973-83.
[72] Lenert PS. Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther. 2006; 8:203.
[73] Lenert PS. Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm. 2010; 2010:
[74] Liu B, Mori I, Hossain MJ, Dong L, Takeda K, Kimura Y. Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cellmediated cytotoxicity. J Gen Virol. 2004; 85: 423-8.
[75] Lu Q, Harrington EO, Rounds S. Apoptosis and lung injury. Keio j Med. 2005; 54: 184-189
[76] Macfarlane DE, Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol. 1998; 160: 1122-31.
[77] Malik Peiris JS. Avian influenza viruses in humans. Rev Sci Tech. 2009; 28:161-73.
[78] Marcus PI, Sekellick MJ. Defective interfering particles with covalently linked [+/-] RNA induce interferon. Nature. 1977; 266: 815-819.
[79] Maris NA, Dessing MC, de Vos AF, Bresser P, van der Zee JS, Jansen HM, Spek CA, van der Poll T: Toll-like receptor mRNA levels in alveolar macrophages after inhalation of endotoxin. Eur Respir J. 2006; 28: 622-626.
[80] Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009; 27: 229-65.
[81] Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Human and avian influenza viruses target different cell types in cultures of humanairway epithelium. Proc Natl Acad Sci U S A. 2004; 101: 4620-4.
[82] Matthay MA, Zimmerman GA, Esmon C, Bhattacharya J, Coller B,Doerschuk CM, Floros J, Gimbrone MA, Jr., Hoffman E, Hubmayr RD, Leppert M, Matalon S, Munford R, Parsons P, Slutsky AS, Tracey KJ, Ward P, Gail DB and Harabin AL. Future Research Directions in Acute Lung Injury:Summary of a National Heart, Lung, and Blood Institute Working Group. Am J Respir Crit Care Med. 2003; 167: 1027-35.
[83] McCoy SL, Kurtz SE, Hausman FA, Trune DR, Bennett RM, Hefeneider SH. Activation of RAW264.7 macrophages by bacterial DNA and lipopolysaccharide increases cell surface DNA binding and internalization. J Biol Chem. 2004; 279: 17217-23.
[84] Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupusautoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005; 115: 407-17.
[85] Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemicinfluenza preparedness. J Infect Dis. 2008; 198: 962-70.
[86] Narula T, Safley M, deBoisblanc BP. H1N1-associated acute respiratory distress syndrome. Am J Med Sci. 2010; 340:499-504.
[87] Neilson D, Kavanagh JP, Rao PN. Kinetics of circulating TNF-alpha and TNF soluble receptors following surgery in a clinical model of sepsis. Cytokine. 1996; 8:938-43.
[88] Nomura N, Miyajima N, Sazuka T, Tanaka A, Kawarabayasi Y, Sato S, Nagase T, Seki N, Ishikawa K, Tabata S. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1. DNA Res. 1994; 1: 47-56.
[89] Nüsslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature. 1980; 287: 795-801.
[90] Pang IK, Iwasaki A. Inflammasomes as mediators of immunity againstinfluenza virus. Trends Immunol. 2011; 32: 34-41.
[91] Patole PS, Zecher D, Pawar RD, Gr?ne HJ, Schl?ndorff D, Anders HJ. G-rich DNA suppresses systemic lupus. J Am Soc Nephrol. 2005; 16:3273-80.
[92] Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, Ng TK, Chan KH, Lai ST, Lim WL, Yuen KY,Guan Y. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet. 2004; 363: 617-9.
[93] Peper RL, Van Campen H. Tumor necrosis factor as a mediator of inflammation in influenza A viral pneumonia. Microb Pathog. 1995; 19: 175-83.
[94] Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Qui?ones-Falconi F, Bautista E, Ramirez-Venegas A, Rojas-Serrano J, Ormsby CE, Corrales A, Higuera A, Mondragon E,Cordova-Villalobos JA. Pneumonia and Respiratory Failure from Swine-Origin Influenza A (H1N1) in Mexico. N Engl J Med. 2009; 361: 680-9.
[95] Perrone LA, Szretter KJ, Katz JM, Mizgerd JP, Tumpey TM. Mice lacking both TNF-аand IL-1 receptors exhibit reduced lung inflammation and delay in onset of death following infection with a highly virulent H5N1 virus. J Infect Dis. 2010; 202: 1161-70.
[96] Peter M, Bode K, Lipford GB, Eberle F, Heeg K, Dalpke AH. Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity. Immunology. 2008; 123:118-28.
[97] Pichlmair A, Schulz O, Tan CP, N?slund TI, Liljestr?m P, Weber F, Reis e Sousa C. RIG-I-mediated antiviral responses to single-stranded RNA bearing 50-phosphates. Science. 2006; 314: 997-1001.
[98] Pisetsky DS, Reich CF. Inhibition of murine macrophage IL-12 production by natural and synthetic DNA. Clin Immunol. 2000; 96:198-204.
[99] Posada C, García-Cruz A, García-Doval I, Millán BS, Teijeira S. Chloroquine-induced myopathy. Lupus. 2011; 20: 773-4.
[100] Pozzolini M, Scarfi S, Benatti U, Giovine M. Interference in MTT cell viability assay in activated macrophage cell line. Anal Biochem. 2003; 313:338–41.
[101] Reed LJ, Muench H. A simple method of estimating fifty per cent end points. Am. J. Hyg. 1938; 27:493-497
[102] Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA. 1998; 95: 588-93.
[103] Ronni T, Sareneva T, Pirhonen J, Julkunen I. Activation of IFN-alpha, IFN-gamma, MxA, and IFN regulatory factor 1 genes in influenza A virus-infected human peripheral blood mononuclear cells. J Immunol. 1995; 154: 2764-74.
[104] Ronni T, Matikainen S, Sareneva T, Melén K, Pirhonen J, Keskinen P, Julkunen I. Regulation of IFN-alpha/beta, MxA, 20, 50-oligoadenylate synthetase, and HLA gene expression in influenza A-infected human lung epithelial cells. J Immunol. 1997; 158: 2363-74.
[105] Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, Wagner H, Bauer S. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol. 2004; 34: 2541-50.
[106] Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K, Dube PH, Xiang Y, Bose S. Activation of innate immune antiviral responses by Nod2. Nat Immunol. 2009; 10: 1073-80.
[107] Salomon R, Hoffmann E, Webster RG. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci U S A. 2007; 104: 12479-81.
[108] Schmitz N, Kurrer M, Bachmann MF, Kopf M. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol. 2005; 79: 6441-8.
[109] Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. NatImmunol. 2001; 2: 947-50.
[110] Schneberger D, Aulakh G, Channabasappa S, et al, Roll of toll-like receptor 9 in mouse lung inflammation in response to chicken barn air, thesis. 2011.
[111] Shirota H, Gursel M, Klinman DM. Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma and IL-12-mediated signaling. J Immunol. 2004; 173: 5002-7.
[112] Shirota H, Gursel I, Gursel M, Klinman DM. Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol. 2005; 174: 4579-83.
[113] Sidwell RW, Smee DF. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res. 2000; 48: 1–16.
[114] Sigel MM, Differences in the hemagglutinating and antigenic properties of strains of influenza virus isolated from one outbreak, J Immunol. 1949; 62: 81–95.
[115] Smith W, Andrewes CH, Laidlaw PP, Timbury MC. A virus obtained from influenza patients. Medical Virology. 1995; 5: 187-191.
[116] Sparwasser T, Miethke T, Lipford G, et al. Bacterial DNA causes septic shock. Nature. 1997; 386: 336–337.
[117] Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity. 2006; 25: 373-81.
[118] Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol. 2006; 6: 9-20.
[119] Stunz LL, Lenert P, Peckham D, Yi AK, Haxhinasto S, Chang M, Krieg AM, Ashman RF. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol. 2002; 32: 1212-22.
[120] Sun J, Madan R, Karp CL, Braciale TJ. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10.Nat Med. 2009; 15: 277-84.
[121] Sun R, Sun L, Bao M, Zhang Y, Wang L, Wu X, Hu D, Liu Y, Yu Y, Wang L. A human microsatellite DNA-mimicking oligodeoxynucleotide with CCT repeats negatively regulates TLR7/9-mediated innate immune responses via selected TLR pathways. Clin Immunol. 2010; 134: 262-76.
[122] Szretter KJ, Gangappa S, Lu X, Smith C, Shieh WJ, Zaki SR, Sambhara S, Tumpey TM, Katz JM. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol. 2007; 81: 2736-44.
[123] Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother. 1999; 44: 11-5.
[124] Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005; 17: 1-14.
[125] Takeda K, Akira S. Toll-like receptors. Curr Protoc Immunol. 2007; Chapter 14: Unit 14.12.
[126] Takizawa T, Matsukawa S, Higuchi Y, Nakamura S, Nakanishi Y, Fukuda R. Induction of programmed cell death (apoptosis) by influenza virus infection in tissue culture cells. J Gen Virol. 1993; 74: 2347-55.
[127] Tamura S, Tanimoto T, Kurata T. Mechanism of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis. 2005; 58: 195-207.
[128] Tasaka S, Kamata H, Miyamoto K, Nakano Y, Shinoda H, Kimizuka Y, Fujiwara H, Hasegawa N, Fujishima S, Miyasho T, Ishizaka A. Intratracheal synthetic CpG oligodeoxynucleotide causes acute lung injury with systemic inflammatory response. Respir Res. 2009; 10: 84.
[129] Taylor RM . Studies on survival of influenza virus between epidemics and antigenic. Am J Public Health Nations Health. 1949; 39:171-8.
[130] Tsujimura H, Tamura T, Kong HJ, Nishiyama A, Ishii KJ, Klinman DM, Ozato K. Toll-like receptor 9 signaling activates NF-kappaB through IFNregulatory factor-8/IFN consensus sequence binding protein in dendritic cells. J Immunol. 2004; 172: 6820-7.
[131] Tukhvatulin AI, Logunov DY, Shcherbinin DN, Shmarov MM, Naroditsky BS, Gudkov AV, Gintsburg AL. Toll-like receptors and their adapter molecules. Biochemistry (Mosc). 2010; 75: 1098-114.
[132] Us D. Cytokine storm in avian influenza. Mikrobiyol Bul. 2008; 42: 365-80.
[133] van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus AD, Kuiken T. H5N1 Virus attachment to lower respiratory tract. Science. 2006; 312: 399.
[134] Wang L, Jiang W, Ding G, Cao H, Lu Y, Luo P, Zhou H, Zheng J. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release. Int Immunopharmacol. 2007; 7: 646-55.
[135] Wang S, Taaffe J, Parker C, Solórzano A, Cao H, García-Sastre A, Lu S. The Hemagglutinin (HA) Proteins from H1 and H3 Serotypes of Influenza A viruses Require Different Antigen Designs for the Induction of the Optimal Protective Antibody Responses as Studied by Codon Optimized HA DNA Vaccines. J Virol. 2006; 80: 11628-11637.
[136] Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR. Double stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J Virol. 2006; 80: 5059-64.
[137] Weighardt H, Kaiser-Moore S, Vabulas RM, Kirschning CJ, Wagner H, Holzmann B. Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J Immunol. 2002; 169: 2823-7.
[138] Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136: 95-103.
[139] Wong JP, Christopher ME, Viswanathan S, Karpoff N, Dai X, Das D, Sun LQ, Wang M, Salazar AM. Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine. 2009; 27: 3481-3.
[140] Xu T, Qiao J, Zhao L, Wang G, He G, Li K, Tian Y, Gao M, Wang J, Wang H, Dong C. Acute respiratory distress syndrome induced by avian influenza A (H5N1) virus in mice. Am J Respir Crit Care Med. 2006; 174: 1011-7.
[141] Yang G, Wan M, Zhang Y, Sun L, Sun R, Hu D, Zhou X, Wang L, Wu X, Wang L, Yu Y. Inhibition of a C-rich oligodeoxynucleotide on activation of immune cells in vitro and enhancement of antibody response in mice. Immunology. 2010; 131: 501-12.
[142] Yi AK, Krieg AM. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J Immunol. 1998; 161: 4493-4497.
[143] Yi AK, Yoon JG, Yeo SJ, Hong SC, English BK, Krieg AM. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J Immunol.2002; 168: 4711-20.
[144] Yi AK, Yoon JG, Krieg AM. Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: regulation by mitogen-activated protein kinases. Int Immunol. 2003; 15: 577-91.
[145] Yumiko M, Elaine WL, and Kanta S.The Mouse Model for Influenza. Current Protocols in Microbiology 15G.3.1-15G.3.30, May 2009
[146] Zeuner RA, Verthelyi D, Gursel M, Ishii KJ, Klinman DM. Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. Arthritis Rheum. 2003; 48:1701-7.
[147] Zhu FG, Reich CF, Pisetsky DS. Inhibition of murine dendritic cellactivation by synthetic phosphorothioate oligodeoxynucleotides. J Leukoc Biol. 2002; 72:1154-63.
[148] Zhu J, Mohan C. Toll-like receptor signaling pathways--therapeutic opportunities. Mediators Inflamm. 2010; 2010:781235
[149] Zeng H, Goldsmith C, Thawatsupha P, Chittaganpitch M, Waicharoen S, Zaki S, Tumpey TM, Katz JM. Highly pathogenic avian influenza H5N1 viruses elicit an attenuated type I interferon response in polarized human bronchial epithelial cells. J Virol. 2007; 81: 12439-49.
[150]胡大利.模拟人微卫星DNA的寡核苷酸对人免疫细胞活化的抑制作用[D].吉林:吉林大学白求恩医学院,2008.
[151]孙然.含CCT基序的寡核苷酸对TLR7/9介导的天然免疫应答的抑制作用[D].吉林:吉林大学白求恩医学院,2009.
[152]杨光.富含胞嗜陡的脱氧寡核普酸对免疫反应的负调节作用[D].吉林:吉林大学白求恩医学院,2009.
[2] Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M, Bouvier M. Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci U S A. 2000; 97:3684-9.
[3] Balasubramanian V, Nguyen LT, Balasubramanian SV, Ramanathan M. Interferon gamma inhibitory oligodeoxynucleotides alter the conformation of interferongamma. Mol Pharmacol. 1998; 53:926-32.
[4] Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O,Coffman RL. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-likereceptors and may promote systemic lupus erythematosus. J Exp Med. 2005; 202:1131-9.
[5] Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol. 2007; 37: 3582-6.
[6] Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS,Kettner JD, Kumar A, Lim M, Shindo N, Penn C, Nicholson KG. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010; 362:1708–19.
[7] Bazin HG, Murray TJ, Bowen WS, Mozaffarian A, Fling SP, Bess LS, Livesay MT, Arnold JS, Johnson CL,Ryter KT, Cluff CW, Evans JT, Johnson DA. The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics. Bioorg Med Chem Lett. 2008;18:5350-4.
[8] Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, Lochindarat S, Nguyen TK, Nguyen TH, Tran TH, Nicoll A, Touch S, Yuen KY. Avian influenza A (H5N1) infection in humans.N. N Engl J Med. 2005; 353: 1374-85.
[9] Blazejewska P, Koscinski L, Viegas N, Anhlan D, Ludwig S, Schughart K. Pathogenicity of different PR8 influenza A virus variants in mice is determined by both viral and host factors. Virology. 2011; 412: 36-45.
[10] Budd A, Alleva L, Alsharifi M, Koskinen A, Smythe V, Müllbacher A, Wood J, Clark I. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother. 2007; 51: 2965-8.
[11] Carey MA, Bradbury JA, Seubert JM, Langenbach R, Zeldin DC,Germolec DR. Contrasting effects of cyclooxygenase-1 (COX-1)and COX-2 deficiency on the host response to influenza A viralinfection. J Immunol. 2005; 175: 6878-84.
[12] Chan MC, Cheung CY, Chui WH, Tsao SW, Nicholls JM, Chan YO, Chan RW, Long HT, Poon LL, Guan Y, Peiris JS. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronehial epithelial cells. Respir Res. 2005; 6: 135.
[13] Chen J, Deng YM. Influenza virus antigenic variation, host antibody production and new approach to control epidemics. Virol J. 2009; 6: 30.
[14] Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF, Gordon S, Guan Y, Peiris JS. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet. 2002; 360: 1831-7.
[15] Choudhury BK, Wild JS, Alam R, Klinman DM, Boldogh I, Dharajiya N, Mileski WJ, Sur S. In vivo role of p38 mitogen-activated protein kinase in mediating the anti-inflammatory effects of CpG oligodeoxynucleotide in murine asthma. J Immunol. 2002; 169: 5955-61.
[16] Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA,Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006; 25:417-28.
[17] Clark IA.How TNF was recognized as a key mechanism of disease.Cytokine Growth Factor Rev. 2007; 18: 335-43.
[18] Couillin I, Vasseur V, Charron S, Gasse P, Tavernier M, Guillet J, Lagente V, Fick L, Jacobs M, Coelho FR, Moser R, Ryffel B. IL-1R1/MyD88 signaling is critical for elastase-induced lung inflammation and emphysema. J Immunol. 2009; 183: 8195-202.
[19] de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Chau NV, Khanh TH, Dong VC, Qui PT, Cam BV, Ha do Q, Guan Y, Peiris JS, Chinh NT, Hien TT, Farrar J. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006; 12: 1203-7.
[20] Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligonucleotides protect against collagen-induced arthritis in mice. Arthritis Rheum. 2004; 50: 1686-9.
[21] Dybing, J.K., Schultz-Cherry, S., Swayne, D.E., Suarez, D.L., Perdue, M.L. Distinct pathogenesis of Hong Kong—origin H5N1 viruses in mice compared to that ofother highly pathogenic H5 avian influenza viruses. J Virol. 2000; 74: 1443-50.
[22] Ferrandiz ML, Foster SJ. Tumor necrosis factor production in a rat airpouch model of inflammation: role of eicosanoids. Agents Actions. 1991; 32:289–294.
[23] Francis T Jr. A new type of virus from epidemic influenza. Science. 1940; 92: 405–408.
[24] Fritz RS, Hayden FG, Calfee DP, Cass LM, Peng AW, Alvord WG, Strober W, Straus SE. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis. 1999; 180: 586-93.
[25] Gambaryan AS, Boravleva EY, Matrosovich TY, Matrosovich MN, Klenk HD, Moiseeva EV, Tuzikov AB, Chinarev AA, Pazynina GV, Bovin NV. Polymer-bound 6_sialyl-N-acetyllactosamine protects mice infectedby influenza virus. Antiviral Res. 2005; 68:116-23.
[26] Gamblin SJ, Skehel JJ. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem. 2010; 285: 28403-9.
[27] Ghedin E, Sengamalay NA, Shumway M, Zaborsky J, Feldblyum T, Subbu V, Spiro DJ, Sitz J, Koo H, Bolotov P, Dernovoy D, Tatusova T, Bao Y, St George K, Taylor J, Lipman DJ, Fraser CM, Taubenberger JK, Salzberg SL.Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature. 2005; 437: 1162-1166.
[28] Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, Si-Tahar M. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem. 2005; 280: 5571-80.
[29] Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F, Klinman DM. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol. 2003; 171:1393-400.
[30] Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F, Klinman DM. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol. 2003; 171: 1393-400.
[31] Haas T, Metzger J, Schmitz F, Heit A, Müller T, Latz E, Wagner H. The DNA sugar backbone 2’deoxyribose determines toll-like receptor 9 activation. Immunity. 2008; 28: 315-23.
[32] Hacker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med. 2000; 192: 595-600.
[33] Halpern MD, Pisetsky DS. In vitro inhibition of murine IFN gamma production by phosphorothioate deoxyguanosine oligomers.Immunopharmacology. 1995; 29: 47-52.
[34] Hashimoto C, Hudson KL, Anderson KV. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell. 1988; 52: 269-79.
[35] Hatta M, Kawaoka Y. Clue to the molecular mechanism of virulence of highly pathogenic H5N1 avian influenza viruses isolated in 2004. Uirusu. 2005; 55: 55-61.
[36] Hatta M, Hatta Y, Kim JH, Watanabe S, Shinya K, Nguyen T, Lien PS, Le QM, Kawaoka Y. Growth of H5N1 influenza A viruses in the upper respiratory tracts of mice. PLoS Pathog. 2007; 3: 1374-9.
[37] Hayashi K, Kadowaki SE, Takei M, Fukuda H. Efficacy of quinolones against secondary pneumococcal pneumonia after influenza virus infection in mice. Antimicrob Agents Chemother. 2006; 50: 748-51.
[38] Heer AK, Shamshiev A, Donda A, Uematsu S, Akira S, Kopf M, Marsland BJ. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J Immunol 2007; 178: 2182-2191.
[39] Heinz S, Haehnel V, Karaghiosoff M, Schwarzfischer L, Müller M, Krause SW, Rehli M. Species-specific regulation of Toll-like receptor 3 genes in men and mice. J Biol Chem. 2003; 278: 21502-9.
[40] Ho PP, Fontoura P, Ruiz PJ, Steinman L, Garren H. An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J Immunol. 2003; 171:4920-6.
[41] Hoppstadter J, Diesel B, Zarbock R, Breinig T, Monz D, Koch M, Meyerhans A, Gortner L, Lehr CM, Huwer H, Kiemer AK. Differential cell reaction upon Toll-like receptor 4 and 9 activation in human alveolar and lung interstitial macrophages. Respir Res. 2010; 11: 124.
[42] Hu D, Su X, Sun R, Yang G, Wang H, Ren J, Sun L, Wu X, Hu X, Yu Y, Wang L. Human microsatellite DNA mimicking oligodeoxynucleotides down-regulate TLR9-dependent and -independent activation of human immune cells. Mol Immunol. 2009; 46: 1387-96.
[43] Hussell T, Pennycook A, Openshaw PJ. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol. 2001; 31: 2566-73.
[44] Inohara, Chamaillard, McDonald C, Nu?ez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem. 2005; 74: 355-83.
[45] Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med. 2002; 76: 105-15.
[46] Julkunen I, Melén K, Nyqvist M, Pirhonen J, Sareneva T, Matikainen S. Inflammatory responses in influenza A virus infection. Vaccine. 2000; 19: 32-7.
[47] Karen H. TLR ligands from the natural world. Nature Reviews Immunology. 2006; 177: 7114-21.
[48] Kash JC, Tumpey TM, Proll SC, Carter V, Perwitasari O, Thomas MJ, Basler CF, Palese P, Taubenberger JK, García-Sastre A, Swayne DE, Katze MG. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature. 2006; 443: 578-81.
[49] Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T, Akira S. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006; 441: 101-5.
[50] Katz JM, Lu X, Frace AM, Morken T, Zaki SR, Tumpey TM. Pathogenesisof and immunity to avian influenza A H5 viruses. Biomed Pharmacother. 2000; 54: 178-87.
[51] Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol. 2009; 21: 317-37.
[52] Kawai T, Akira S. Toll-like receptor downstream signaling. Arthritis Res Ther. 2005; 7: 12-9.
[53] Kawaoka Y, Krauss S, Webster RG. Avian-to-human transmission of thePB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol. 1989; 63: 4603-8.
[54] Kido H, Yokogoshi Y, Sakai K, Tashiro M, Kishino Y, Fukutomi A, Katunuma N. Isolation and characterization of a noveltrypsin-like protease found in rat bronchiolar epithelial clara cells. J Biol Chem. 1992; 267: 13573-9.
[55] Killian ML. Hemagglutination Assay for the Avian Influenza Virus. Methods Mol Biol. 2008; 436: 47-52.
[56] Klinman DM, Tross D, Klaschik S, Shirota H, Sato T. Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides.Ann N Y Acad Sci. 2009; 1175: 80-8.
[57] Knuefermann P, Baumgarten G, Koch A, Schwederski M, Velten M, Ehrentraut H, Mersmann J, Meyer R, Hoeft A, Zacharowski K, GrohéC. CpG oligonucleotide activates Toll-like receptor 9 and causes lung inflammation in vivo. Respir Res. 2007; 8: 72.
[58] Korteweg C, Gu J. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am J Pathol, 2008; 172: 1155-1170
[59] Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara H, Hatta Y, Kim JH, Halfmann P, Hatta M,Feldmann F, Alimonti JB, Fernando L, Li Y, Katze MG, Feldmann H, Kawaoka Y. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature. 2007; 445: 319-23.
[60] Korteweg C, Gu J. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am J Pathol. 2008; 172: 1155-70.
[61] Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, Yi AK, Short D, Davis HL. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci. 1998; 95:12631-6.
[62] Krieg AM. CpG DNA: a pathogenic factor in systemic lupus erythematosus?J Clin Immunol. 1995; 15: 284-92.
[63] Krysko DV, Kaczmarek A, Krysko O, Heyndrickx L, Woznicki J, Bogaert P, Cauwels A, Takahashi N, Magez S, Bachert C, Vandenabeele P. TLR-2 and TLR-9 are sensors of apoptosis in a mouse model of doxorubicin-induced acute inflammation. Cell Death Differ. 2011; 18: 1316-25.
[64] Lafferty EI, Qureshi ST, Schnare M. The role of toll-like receptors in acute and chronic lung inflammation.J Inflamm. 2010; 7: 57.
[65] Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T,Golenbock DT. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 2004; 5:190-8.
[66] Lenert P. Inhibitory oligodeoxynucleotides-therapeutic promise for systemic autoimmune diseases? Clin Exp Immunol. 2005; 140:1-10.
[67] Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, Flavell R,Chignard M, Si-Tahar M. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog 2006:2:e53.
[68] Le Goffic R, Pothlichet J, Vitour D, Fujita T, Meurs E, Chignard M, Si-Tahar M.Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J Immunol. 2007; 178: 3368-72.
[69] Le Goffic R, Pothlichet J, Vitour D, Fujita T, Meurs E, Chignard M, Si-Tahar M. Cutting edge: influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J Immunol. 2007; 178: 3368-72.
[70] Lee N, Wong CK, Chan PK, Lun SW, Lui G, Wong B, Hui DS, Lam CW, Cockram CS, Choi KW, Yeung AC,Tang JW, Sung JJ. Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. Clin InfectDis. 2007; 45: 723-31.
[71] Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette sp?tzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell. 1996; 86: 973-83.
[72] Lenert PS. Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther. 2006; 8:203.
[73] Lenert PS. Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm. 2010; 2010:
[74] Liu B, Mori I, Hossain MJ, Dong L, Takeda K, Kimura Y. Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cellmediated cytotoxicity. J Gen Virol. 2004; 85: 423-8.
[75] Lu Q, Harrington EO, Rounds S. Apoptosis and lung injury. Keio j Med. 2005; 54: 184-189
[76] Macfarlane DE, Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol. 1998; 160: 1122-31.
[77] Malik Peiris JS. Avian influenza viruses in humans. Rev Sci Tech. 2009; 28:161-73.
[78] Marcus PI, Sekellick MJ. Defective interfering particles with covalently linked [+/-] RNA induce interferon. Nature. 1977; 266: 815-819.
[79] Maris NA, Dessing MC, de Vos AF, Bresser P, van der Zee JS, Jansen HM, Spek CA, van der Poll T: Toll-like receptor mRNA levels in alveolar macrophages after inhalation of endotoxin. Eur Respir J. 2006; 28: 622-626.
[80] Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009; 27: 229-65.
[81] Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Human and avian influenza viruses target different cell types in cultures of humanairway epithelium. Proc Natl Acad Sci U S A. 2004; 101: 4620-4.
[82] Matthay MA, Zimmerman GA, Esmon C, Bhattacharya J, Coller B,Doerschuk CM, Floros J, Gimbrone MA, Jr., Hoffman E, Hubmayr RD, Leppert M, Matalon S, Munford R, Parsons P, Slutsky AS, Tracey KJ, Ward P, Gail DB and Harabin AL. Future Research Directions in Acute Lung Injury:Summary of a National Heart, Lung, and Blood Institute Working Group. Am J Respir Crit Care Med. 2003; 167: 1027-35.
[83] McCoy SL, Kurtz SE, Hausman FA, Trune DR, Bennett RM, Hefeneider SH. Activation of RAW264.7 macrophages by bacterial DNA and lipopolysaccharide increases cell surface DNA binding and internalization. J Biol Chem. 2004; 279: 17217-23.
[84] Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupusautoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005; 115: 407-17.
[85] Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemicinfluenza preparedness. J Infect Dis. 2008; 198: 962-70.
[86] Narula T, Safley M, deBoisblanc BP. H1N1-associated acute respiratory distress syndrome. Am J Med Sci. 2010; 340:499-504.
[87] Neilson D, Kavanagh JP, Rao PN. Kinetics of circulating TNF-alpha and TNF soluble receptors following surgery in a clinical model of sepsis. Cytokine. 1996; 8:938-43.
[88] Nomura N, Miyajima N, Sazuka T, Tanaka A, Kawarabayasi Y, Sato S, Nagase T, Seki N, Ishikawa K, Tabata S. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1. DNA Res. 1994; 1: 47-56.
[89] Nüsslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature. 1980; 287: 795-801.
[90] Pang IK, Iwasaki A. Inflammasomes as mediators of immunity againstinfluenza virus. Trends Immunol. 2011; 32: 34-41.
[91] Patole PS, Zecher D, Pawar RD, Gr?ne HJ, Schl?ndorff D, Anders HJ. G-rich DNA suppresses systemic lupus. J Am Soc Nephrol. 2005; 16:3273-80.
[92] Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, Ng TK, Chan KH, Lai ST, Lim WL, Yuen KY,Guan Y. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet. 2004; 363: 617-9.
[93] Peper RL, Van Campen H. Tumor necrosis factor as a mediator of inflammation in influenza A viral pneumonia. Microb Pathog. 1995; 19: 175-83.
[94] Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Qui?ones-Falconi F, Bautista E, Ramirez-Venegas A, Rojas-Serrano J, Ormsby CE, Corrales A, Higuera A, Mondragon E,Cordova-Villalobos JA. Pneumonia and Respiratory Failure from Swine-Origin Influenza A (H1N1) in Mexico. N Engl J Med. 2009; 361: 680-9.
[95] Perrone LA, Szretter KJ, Katz JM, Mizgerd JP, Tumpey TM. Mice lacking both TNF-аand IL-1 receptors exhibit reduced lung inflammation and delay in onset of death following infection with a highly virulent H5N1 virus. J Infect Dis. 2010; 202: 1161-70.
[96] Peter M, Bode K, Lipford GB, Eberle F, Heeg K, Dalpke AH. Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity. Immunology. 2008; 123:118-28.
[97] Pichlmair A, Schulz O, Tan CP, N?slund TI, Liljestr?m P, Weber F, Reis e Sousa C. RIG-I-mediated antiviral responses to single-stranded RNA bearing 50-phosphates. Science. 2006; 314: 997-1001.
[98] Pisetsky DS, Reich CF. Inhibition of murine macrophage IL-12 production by natural and synthetic DNA. Clin Immunol. 2000; 96:198-204.
[99] Posada C, García-Cruz A, García-Doval I, Millán BS, Teijeira S. Chloroquine-induced myopathy. Lupus. 2011; 20: 773-4.
[100] Pozzolini M, Scarfi S, Benatti U, Giovine M. Interference in MTT cell viability assay in activated macrophage cell line. Anal Biochem. 2003; 313:338–41.
[101] Reed LJ, Muench H. A simple method of estimating fifty per cent end points. Am. J. Hyg. 1938; 27:493-497
[102] Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA. 1998; 95: 588-93.
[103] Ronni T, Sareneva T, Pirhonen J, Julkunen I. Activation of IFN-alpha, IFN-gamma, MxA, and IFN regulatory factor 1 genes in influenza A virus-infected human peripheral blood mononuclear cells. J Immunol. 1995; 154: 2764-74.
[104] Ronni T, Matikainen S, Sareneva T, Melén K, Pirhonen J, Keskinen P, Julkunen I. Regulation of IFN-alpha/beta, MxA, 20, 50-oligoadenylate synthetase, and HLA gene expression in influenza A-infected human lung epithelial cells. J Immunol. 1997; 158: 2363-74.
[105] Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, Wagner H, Bauer S. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol. 2004; 34: 2541-50.
[106] Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K, Dube PH, Xiang Y, Bose S. Activation of innate immune antiviral responses by Nod2. Nat Immunol. 2009; 10: 1073-80.
[107] Salomon R, Hoffmann E, Webster RG. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci U S A. 2007; 104: 12479-81.
[108] Schmitz N, Kurrer M, Bachmann MF, Kopf M. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol. 2005; 79: 6441-8.
[109] Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. NatImmunol. 2001; 2: 947-50.
[110] Schneberger D, Aulakh G, Channabasappa S, et al, Roll of toll-like receptor 9 in mouse lung inflammation in response to chicken barn air, thesis. 2011.
[111] Shirota H, Gursel M, Klinman DM. Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma and IL-12-mediated signaling. J Immunol. 2004; 173: 5002-7.
[112] Shirota H, Gursel I, Gursel M, Klinman DM. Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol. 2005; 174: 4579-83.
[113] Sidwell RW, Smee DF. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res. 2000; 48: 1–16.
[114] Sigel MM, Differences in the hemagglutinating and antigenic properties of strains of influenza virus isolated from one outbreak, J Immunol. 1949; 62: 81–95.
[115] Smith W, Andrewes CH, Laidlaw PP, Timbury MC. A virus obtained from influenza patients. Medical Virology. 1995; 5: 187-191.
[116] Sparwasser T, Miethke T, Lipford G, et al. Bacterial DNA causes septic shock. Nature. 1997; 386: 336–337.
[117] Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity. 2006; 25: 373-81.
[118] Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol. 2006; 6: 9-20.
[119] Stunz LL, Lenert P, Peckham D, Yi AK, Haxhinasto S, Chang M, Krieg AM, Ashman RF. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol. 2002; 32: 1212-22.
[120] Sun J, Madan R, Karp CL, Braciale TJ. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10.Nat Med. 2009; 15: 277-84.
[121] Sun R, Sun L, Bao M, Zhang Y, Wang L, Wu X, Hu D, Liu Y, Yu Y, Wang L. A human microsatellite DNA-mimicking oligodeoxynucleotide with CCT repeats negatively regulates TLR7/9-mediated innate immune responses via selected TLR pathways. Clin Immunol. 2010; 134: 262-76.
[122] Szretter KJ, Gangappa S, Lu X, Smith C, Shieh WJ, Zaki SR, Sambhara S, Tumpey TM, Katz JM. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol. 2007; 81: 2736-44.
[123] Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother. 1999; 44: 11-5.
[124] Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005; 17: 1-14.
[125] Takeda K, Akira S. Toll-like receptors. Curr Protoc Immunol. 2007; Chapter 14: Unit 14.12.
[126] Takizawa T, Matsukawa S, Higuchi Y, Nakamura S, Nakanishi Y, Fukuda R. Induction of programmed cell death (apoptosis) by influenza virus infection in tissue culture cells. J Gen Virol. 1993; 74: 2347-55.
[127] Tamura S, Tanimoto T, Kurata T. Mechanism of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis. 2005; 58: 195-207.
[128] Tasaka S, Kamata H, Miyamoto K, Nakano Y, Shinoda H, Kimizuka Y, Fujiwara H, Hasegawa N, Fujishima S, Miyasho T, Ishizaka A. Intratracheal synthetic CpG oligodeoxynucleotide causes acute lung injury with systemic inflammatory response. Respir Res. 2009; 10: 84.
[129] Taylor RM . Studies on survival of influenza virus between epidemics and antigenic. Am J Public Health Nations Health. 1949; 39:171-8.
[130] Tsujimura H, Tamura T, Kong HJ, Nishiyama A, Ishii KJ, Klinman DM, Ozato K. Toll-like receptor 9 signaling activates NF-kappaB through IFNregulatory factor-8/IFN consensus sequence binding protein in dendritic cells. J Immunol. 2004; 172: 6820-7.
[131] Tukhvatulin AI, Logunov DY, Shcherbinin DN, Shmarov MM, Naroditsky BS, Gudkov AV, Gintsburg AL. Toll-like receptors and their adapter molecules. Biochemistry (Mosc). 2010; 75: 1098-114.
[132] Us D. Cytokine storm in avian influenza. Mikrobiyol Bul. 2008; 42: 365-80.
[133] van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus AD, Kuiken T. H5N1 Virus attachment to lower respiratory tract. Science. 2006; 312: 399.
[134] Wang L, Jiang W, Ding G, Cao H, Lu Y, Luo P, Zhou H, Zheng J. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release. Int Immunopharmacol. 2007; 7: 646-55.
[135] Wang S, Taaffe J, Parker C, Solórzano A, Cao H, García-Sastre A, Lu S. The Hemagglutinin (HA) Proteins from H1 and H3 Serotypes of Influenza A viruses Require Different Antigen Designs for the Induction of the Optimal Protective Antibody Responses as Studied by Codon Optimized HA DNA Vaccines. J Virol. 2006; 80: 11628-11637.
[136] Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR. Double stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J Virol. 2006; 80: 5059-64.
[137] Weighardt H, Kaiser-Moore S, Vabulas RM, Kirschning CJ, Wagner H, Holzmann B. Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J Immunol. 2002; 169: 2823-7.
[138] Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136: 95-103.
[139] Wong JP, Christopher ME, Viswanathan S, Karpoff N, Dai X, Das D, Sun LQ, Wang M, Salazar AM. Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine. 2009; 27: 3481-3.
[140] Xu T, Qiao J, Zhao L, Wang G, He G, Li K, Tian Y, Gao M, Wang J, Wang H, Dong C. Acute respiratory distress syndrome induced by avian influenza A (H5N1) virus in mice. Am J Respir Crit Care Med. 2006; 174: 1011-7.
[141] Yang G, Wan M, Zhang Y, Sun L, Sun R, Hu D, Zhou X, Wang L, Wu X, Wang L, Yu Y. Inhibition of a C-rich oligodeoxynucleotide on activation of immune cells in vitro and enhancement of antibody response in mice. Immunology. 2010; 131: 501-12.
[142] Yi AK, Krieg AM. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J Immunol. 1998; 161: 4493-4497.
[143] Yi AK, Yoon JG, Yeo SJ, Hong SC, English BK, Krieg AM. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J Immunol.2002; 168: 4711-20.
[144] Yi AK, Yoon JG, Krieg AM. Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: regulation by mitogen-activated protein kinases. Int Immunol. 2003; 15: 577-91.
[145] Yumiko M, Elaine WL, and Kanta S.The Mouse Model for Influenza. Current Protocols in Microbiology 15G.3.1-15G.3.30, May 2009
[146] Zeuner RA, Verthelyi D, Gursel M, Ishii KJ, Klinman DM. Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. Arthritis Rheum. 2003; 48:1701-7.
[147] Zhu FG, Reich CF, Pisetsky DS. Inhibition of murine dendritic cellactivation by synthetic phosphorothioate oligodeoxynucleotides. J Leukoc Biol. 2002; 72:1154-63.
[148] Zhu J, Mohan C. Toll-like receptor signaling pathways--therapeutic opportunities. Mediators Inflamm. 2010; 2010:781235
[149] Zeng H, Goldsmith C, Thawatsupha P, Chittaganpitch M, Waicharoen S, Zaki S, Tumpey TM, Katz JM. Highly pathogenic avian influenza H5N1 viruses elicit an attenuated type I interferon response in polarized human bronchial epithelial cells. J Virol. 2007; 81: 12439-49.
[150]胡大利.模拟人微卫星DNA的寡核苷酸对人免疫细胞活化的抑制作用[D].吉林:吉林大学白求恩医学院,2008.
[151]孙然.含CCT基序的寡核苷酸对TLR7/9介导的天然免疫应答的抑制作用[D].吉林:吉林大学白求恩医学院,2009.
[152]杨光.富含胞嗜陡的脱氧寡核普酸对免疫反应的负调节作用[D].吉林:吉林大学白求恩医学院,2009.